» Articles » PMID: 8168083

Androgen-independent Cancer Progression and Bone Metastasis in the LNCaP Model of Human Prostate Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 1994 May 15
PMID 8168083
Citations 347
Authors
Affiliations
Soon will be listed here.
Abstract

Our laboratory has previously reported on the derivation of LNCaP cell sublines from LNCaP tumors maintained in castrated and intact athymic male mice. These LNCaP sublines differ from the parental line in tumorigenicity and androgen dependence. This paper demonstrates that one of these sublines acquired metastatic potential. When inoculated either s.c. or orthotopically, the C4-2 subline metastasized to the lymph node and bone with an incidence of 11-50%. Interestingly, the incidence of osseous metastasis was higher in castrated than in intact male hosts. We evaluated the chromosomal, immunohistochemical, and biochemical characteristics of the LNCaP sublines derived from C4-2 tumors that metastasized to the lymph node and bone. Cytogenetic analysis showed that all sublines were human and shared common marker chromosomes with the parental LNCaP cells. This experimental human prostate cancer model may permit, for the first time, the study of the molecular mechanisms underlying human prostate cancer metastasis.

Citing Articles

H2AJ Is a Direct Androgen Receptor Target Gene That Regulates Androgen-Induced Cellular Senescence and Inhibits Mesenchymal Markers in Prostate Cancer Cells.

Heidari Horestani M, Atri Roozbahani G, Baniahmad A Cancers (Basel). 2025; 17(5).

PMID: 40075640 PMC: 11898987. DOI: 10.3390/cancers17050791.


Application of Original Prostate Cancer Progression Model Interacting with Fibroblasts in Preclinical Research.

Ishii K, Iguchi K, Matsuda C, Hirokawa Y, Sugimura Y, Watanabe M J Clin Med. 2025; 13(24.

PMID: 39768760 PMC: 11678552. DOI: 10.3390/jcm13247837.


A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.

Dutta S, Khedmatgozar H, Patel G, Latour D, Welsh J, Mustafi M Oncogene. 2024; .

PMID: 39702503 DOI: 10.1038/s41388-024-03252-5.


Metastatic hormone-naïve prostate cancer: a distinct biological entity.

Corres-Mendizabal J, Zacchi F, Martin-Martin N, Mateo J, Carracedo A Trends Cancer. 2024; 10(9):825-841.

PMID: 39048488 PMC: 11397905. DOI: 10.1016/j.trecan.2024.06.005.


To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics.

Kurganovs N, Engedal N Front Pharmacol. 2024; 15:1419806.

PMID: 38910881 PMC: 11190189. DOI: 10.3389/fphar.2024.1419806.